[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Wekerle, 2008 - Google Patents

Lessons from multiple sclerosis: models, concepts, observations

Wekerle, 2008

Document ID
6233993909571854723
Author
Wekerle H
Publication year
Publication venue
Annals of the rheumatic diseases

External Links

Snippet

Experimental autoimmune encephalomyelitis (EAE) is often termed “the” model of human multiple sclerosis (MS). This is, however, an oversimplification. MS is a multifaceted disorder, with no single experimental model representing the entire complexity of the human …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Similar Documents

Publication Publication Date Title
Wekerle Lessons from multiple sclerosis: models, concepts, observations
Feins et al. An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer
US20240165158A1 (en) Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases
Sharabi et al. Regulatory T cells in the treatment of disease
Hohlfeld et al. The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets
Herold et al. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes
Parsa et al. Adoptive transfer of immunomodulatory M2 macrophages prevents type 1 diabetes in NOD mice
Gold et al. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research
Serr et al. A miRNA181a/NFAT5 axis links impaired T cell tolerance induction with autoimmune type 1 diabetes
Mannering et al. The case for an autoimmune aetiology of type 1 diabetes
US20200352999A1 (en) Use and production of engineered immune cells to disrupt nfat-ap1 pathway transcription factors
Wolbert et al. Deciphering immune mechanisms in chronic inflammatory demyelinating polyneuropathies
Nakayama et al. Germline TRAV5D-4 T-cell receptor sequence targets a primary insulin peptide of NOD mice
Redondo-García et al. Human leukocyte immunoglobulin-like receptors in health and disease
Nakayama et al. Determining antigen specificity of human islet infiltrating T cells in type 1 diabetes
Wekerle et al. The immunology of inflammatory demyelinating disease
Wardell et al. Harnessing the biology of regulatory T cells to treat disease
CA2743502A1 (en) Foxp3+ natural killer t-cells and the treatment of immune related diseases
Segal et al. Toward curing neurological autoimmune disorders: Biomarkers, immunological mechanisms, and therapeutic targets
Matsuda et al. Approaches for controlling antibody-mediated allograft rejection through targeting B cells
Martinez et al. FOXP3+ regulatory T cells use heparanase to access IL-2 bound to ECM in inflamed tissues
Suan et al. Can autoimmune disease be cured by deep CD19+ cell depletion?
Clemente Casares pMHC-class II nanovaccine to treat autoimmune diseases
Holmoy et al. Genetic and molecular approaches to the immunopathogenesis of multiple sclerosis: an update
Felton et al. B Quiet: Autoantigen-Specific Strategies to Silence Raucous B Lymphocytes and Halt Cross-Talk with T Cells in Type 1 Diabetes. Biomedicines 2021, 9, 42